Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.08 -0.02 (-1.82%)
As of: Sep 4, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Gross Margin (QoQ) (2011 - 2026)

Analysis

Lineage Cell Therapeutics (LCTX) Gross Margin (QoQ) (2011 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.71 Mn 213.99 Mn 1.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.00
Mar 31, 2026 100.00
Dec 31, 2025 -86.00
Sep 30, 2025 127.00
Jun 30, 2025 99.00
Mar 31, 2025 297.00
Dec 31, 2024 -436.00
Sep 30, 2024 212.00
Jun 30, 2024 366.00
Mar 31, 2024 547.00
Dec 31, 2023 130.00
Sep 30, 2023 -963.00
Jun 30, 2023 105.00
Mar 31, 2023 34.00
Dec 31, 2022 251.00
Sep 30, 2022 -312.00
Jun 30, 2022 -136.00
Mar 31, 2022 9,471.00
Dec 31, 2021 -5,468.00
Sep 30, 2021 -1,898.00